Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome.
Russell LJ, Enshaei A, Jones L, Erhorn A, Masic D, Bentley H, Laczko KS, Fielding AK, Goldstone AH, Goulden N, Mitchell CD, Wade R, Vora A, Moorman AV, Harrison CJ. Russell LJ, et al. Among authors: goulden n. J Clin Oncol. 2014 May 10;32(14):1453-62. doi: 10.1200/JCO.2013.51.3242. Epub 2014 Apr 7. J Clin Oncol. 2014. PMID: 24711557
Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD, Goulden N, Vora A, Harrison CJ. Moorman AV, et al. Among authors: goulden n. J Clin Oncol. 2013 Sep 20;31(27):3389-96. doi: 10.1200/JCO.2013.48.9377. Epub 2013 Aug 12. J Clin Oncol. 2013. PMID: 23940220
EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ. Schwab C, et al. Among authors: goulden n. Blood. 2016 May 5;127(18):2214-8. doi: 10.1182/blood-2015-09-670166. Epub 2016 Feb 12. Blood. 2016. PMID: 26872634 Free article.
Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, Moppett J, Hough R, Rowntree C, Hancock J, Goulden N, Samarasinghe S, Vora A. Moorman AV, et al. Among authors: goulden n. J Clin Oncol. 2022 Dec 20;40(36):4228-4239. doi: 10.1200/JCO.22.00245. Epub 2022 Jun 17. J Clin Oncol. 2022. PMID: 35714315 Clinical Trial.
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R. Vora A, et al. Among authors: goulden n. Lancet Oncol. 2014 Jul;15(8):809-18. doi: 10.1016/S1470-2045(14)70243-8. Epub 2014 Jun 9. Lancet Oncol. 2014. PMID: 24924991 Clinical Trial.
134 results